Mechanism of anti-hypertensive effect of standardised aqueous ethanolic extract of ficus deltoidea trengganuensis in spontaneously hypertensive rats

• Main Author: Zurain Radjeni (Author)
• Format: Thesis Book
• Language: English
• Published: Sungai Buloh, Selangor Universiti Teknologi MARA. Faculty of Medicine 2019
• Subjects: Antihypertensive Agents; Plants, Medicinal > therapeutic use; Hypertension
• Online Access: Click Here to View Status and Holdings.
• Item Description: UiTM Digitized
• Physical Description: xiv, 100 pages illustrations (some color), charts 30 cm
• Bibliography: Includes bibliographical references (page 69-99)

The leaves of Ficus deltoidea are often used in traditional medicine for the treatment of a number of ailments. However, evidence about its anti-hypertensive activity remains undetermined although its extract has been shown to have angiotensin converting enzyme (ACE) inhibitory activity in vitro. This study therefore investigates the anti-hypertensive effect of a standardised aqueous ethanolic extract of the leaves of Ficus deltoidea Trengganuensis (FDT) in Spontaneously Hypertensive Rats (SHRs). Thirty, male SHRs, aged 12 to 14 weeks, weighing 220 to 270g and with a systolic blood pressure (SBP) of greater than 150 mmHg were divided into 5 groups (n=6). Each group was treated daily, via the oral route, for 4 weeks either with 800, 1000 or 1200 mg/kg body weight of standardised aqueous ethanolic extract of leaves of FDT. Controls were given either 10 mg/kg body weight of losartan or 0.5 ml of distilled water. Blood pressure was measured weekly using tail cuff plethysmography. Urinary and serum calcium, sodium, potassium and total protein concentrations were analysed. Endothelial nitric oxide synthase (NOS), endothelin 1 (ET-1) concentrations, total antioxidant status (TAS) and major components of the renin- angiotensin-aldosterone system (RAAS), including renin, ACE, angiotensin (Ang) I, ACE2, Ang II and aldosterone were determined using ELISA. Data were analysed using ANOVA. SBP was significantly lower at week 4 in rats receiving 1200 mg FDT (p<0.05) or losartan (p<0.001) when compared with that in the controls. No significant differences were evident in body weight and urine output between the groups. There were also no significant differences in urinary and serum calcium, sodium, potassium and total protein excretion rates between the groups. No significant differences were evident in concentrations of components of RAAS when compared with that in the control groups. However, the concentrations of ET-1, eNOS and TAS were significantly lower in FDT treated rats. In conclusion, daily oral administration of 1200 mg FDT for four weeks significantly lowers blood pressure in SHR. However, it is unlikely to involve the RAAS or electrolyte excretion as no differences were detected in any of these between control and treated rats. The precise mechanism therefore remains to be determined